VPA response in SMA is suppressed by the fatty acid translocase CD36

Human Molecular Genetics

Volumn 22, Issue 2, 2013, Pages 398-407

  Garbes, Lutz ^a   Heesen, Ludwig ^a,d   Hölker, Irmgard ^a   Bauer, Tim ^a   Schreml, Julia ^a   Zimmermann, Katharina ^a   Thoenes, Michaela ^a   Walter, Michael ^b   Dimos, John ^c   Peitz, Michael ^d   Brüstle, Oliver ^d   Heller, Raoul ^a   Wirth, Brunhilde ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c IPierian Inc   (United States)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CD36 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; SHORT CHAIN FATTY ACID; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; VALPROIC ACID;

ARTICLE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; FIBROBLAST; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL MUSCULAR ATROPHY;

ANTIGENS, CD36; CELL LINE; FIBROBLASTS; GABAERGIC NEURONS; GENE EXPRESSION PROFILING; HUMANS; MUSCULAR ATROPHY, SPINAL; VALPROIC ACID;

IPS;

EID: 84871591068     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds437     Document Type: Article

References (50)

1. Munsat, T. and Davies, K. (1996) Spinal muscular atrophy. 32nd ENMC International Workshop. Naarden, The Netherlands, 10-12 March 1995. Neuromuscul. Disord., 6, 125-7.
2. Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T.F. and Wirth, B. (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet., 70, 358-68.
3. Hendrickson, B.C., Donohoe, C., Akmaev, V.R., Sugarman, E.A., Labrousse, P., Boguslavskiy, L., Flynn, K., Rohlfs, E.M., Walker, A., Allitto, B. et al. (2009) Differences in SMN1 allele frequencies among ethnic groups within North America. J. Med. Genet., 46, 641-4.
4. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M. et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80, 155-65.
5. Wirth, B. (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat., 15, 228-37.
6. Chen, Q., Baird, S.D., Mahadevan, M., Besner-Johnston, A., Farahani, R., Xuan, J., Kang, X., Lefebvre, C., Ikeda, J.E., Korneluk, R.G. et al. (1998) Sequence of a 131-kb region of 5q13.1 containing the spinal muscular atrophy candidate genes SMN and NAIP. Genomics, 48, 121-7.
7. Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Munnich, A., Dreyfuss, G. and Melki, J. (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet., 16, 265-9.
8. Lorson, C.L., Hahnen, E., Androphy, E.J. and Wirth, B. (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA, 96, 6307-11.
9. Brichta, L., Holker, I., Haug, K., Klockgether, T. and Wirth, B. (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol., 59, 970-5.
10. Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Eyupoglu, I.Y. and Wirth, B. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet., 12, 2481-9.
11. Swoboda, K.J., Scott, C.B., Reyna, S.P., Prior, T.W., LaSalle, B., Sorenson, S.L., Wood, J., Acsadi, G., Crawford, T.O., Kissel, J.T. et al. (2009) Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One, 4, e5268.
12. Kissel, J.T., Scott, C.B., Reyna, S.P., Crawford, T.O., Simard, L.R., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., D'Anjou, G. et al. (2011) SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One, 6, e21296.
13. Swoboda, K.J., Scott, C.B., Crawford, T.O., Simard, L.R., Reyna, S.P., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., D'Anjou, G. et al. (2010) SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One, 5, e12140.
14. Darbar, I.A., Plaggert, P.G., Resende, M.B., Zanoteli, E. and Reed, U.C. (2011) Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol., 11, 36.
15. Sumner, C.J., Huynh, T.N., Markowitz, J.A., Perhac, J.S., Hill, B., Coovert, D.D., Schussler, K., Chen, X., Jarecki, J., Burghes, A.H. et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol., 54, 647-54.
16. Piepers, S., Cobben, J.M., Sodaar, P., Jansen, M.D., Wadman, R.I., Meester-Delver, A., Poll-The, B.T., Lemmink, H.H., Wokke, J.H., van der Pol, W.L. et al. (2011) Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. J. Neurol. Neurosurg. Psychiatry, 82, 850-2.
17. Swoboda, K.J., Scott, C.B., Crawford, T.O., Simard, L.R., Reyna, S.P., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., D'Anjou, G. et al. (2011) SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One, 5, e12140.
18. Weihl, C.C., Connolly, A.M. and Pestronk, A. (2006) Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology, 67, 500-1.
19. Takahashi, K., Okita, K., Nakagawa, M. and Yamanaka, S. (2007) Induction of pluripotent stem cells from fibroblast cultures. Nat. Protoc., 2, 3081-9.
20. Koch, P., Opitz, T., Steinbeck, J.A., Ladewig, J. and Brustle, O. (2009) A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc. Natl Acad. Sci. USA, 106, 3225-30.
21. Johannessen, C.U. (2000) Mechanisms of action of valproate: a commentatory. Neurochem. Int., 37, 103-10.
22. Garbes, L., Riessland, M., Holker, I., Heller, R., Hauke, J., Trankle, C., Coras, R., Blumcke, I., Hahnen, E. and Wirth, B. (2009) LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet., 18, 3645-58.
23. Riessland, M., Brichta, L., Hahnen, E. and Wirth, B. (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet., 120, 101-10.
24. Boeckeler, K., Adley, K., Xu, X., Jenkins, A., Jin, T. and Williams, R.S. (2006) The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum. Eur. J. Cell Biol., 85, 1047-57.
25. Coburn, C.T., Knapp, F.F. Jr., Febbraio, M., Beets, A.L., Silverstein, R.L. and Abumrad, N.A. (2000) Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem., 275, 32523-9.
26. Hoosdally, S.J., Andress, E.J., Wooding, C., Martin, C.A. and Linton, K.J. (2009) The human scavenger receptor CD36: glycosylation status and its role in trafficking and function. J. Biol. Chem., 284, 16277-88.
27. Abumrad, N.A., el-Maghrabi, M.R., Amri, E.Z., Lopez, E. and Grimaldi, P.A. (1993) Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem., 268, 17665-8.
28. Endemann, G., Stanton, L.W., Madden, K.S., Bryant, C.M., White, R.T. and Protter, A.A. (1993) CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem., 268, 11811-6.
29. Meunier, H., Carraz, G., Neunier, Y., Eymard, P. and Aimard, M. (1963) [Pharmacodynamic properties of N-dipropylacetic acid]. Therapie, 18, 435-8.
30. Tsai, L.K., Yang, C.C., Hwu, W.L. and Li, H. (2007) Valproic acid treatment in six patients with spinal muscular atrophy. Eur. J. Neurol., 14, e8-e9.
31. Wadman, R.I., Bosboom, W.M., van den Berg, L.H., Wokke, J.H., Iannaccone, S.T. and Vrancken, A.F. (2012) Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst. Rev. Art. No.: CD006282.
32. Sumner, C.J., Kolb, S.J., Harmison, G.G., Jeffries, N.O., Schadt, K., Finkel, R.S., Dreyfuss, G. and Fischbeck, K.H. (2006) SMN mRNA and protein levels in peripheral blood. Biomarkers for SMA clinical trials. Neurology, 66, 1067-73.
33. Riessland, M., Ackermann, B., Forster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., Hahnen, E. et al. (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet., 19, 1492-506.
34. Mattis, V.B., Ebert, A.D., Fosso, M.Y., Chang, C.W. and Lorson, C.L. (2009) Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum. Mol. Genet., 18, 3906-13.
35. Krosschell, K.J., Maczulski, J.A., Crawford, T.O., Scott, C. and Swoboda, K.J. (2006) A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord., 16, 417-26.
36. Also-Rallo, E., Alias, L., Martinez-Hernandez, R., Caselles, L., Barcelo, M.J., Baiget, M., Bernal, S. and Tizzano, E.F. (2011) Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability. Eur. J. Hum. Genet., 19, 1059-65.
37. Robinton, D.A. and Daley, G.Q. (2012) The promise of induced pluripotent stem cells in research and therapy. Nature, 481, 295-305.
38. Ebert, A.D., Yu, J., Rose, F.F. Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A. and Svendsen, C.N. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 457, 277-80.
39. Mostoslavsky, G. (2011) Concise review: the magic act of generating induced pluripotent stem cells: many rabbits in the hat. Stem Cells, 30, 28-32.
40. Ellis, L., Pan, Y., Smyth, G.K., George, D.J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G. et al. (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res., 14, 4500-10.
41. Silverstein, R.L., Baird, M., Lo, S.K. and Yesner, L.M. (1992) Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor. J Biol Chem., 267, 16607-12.
42. Means, T.K., Mylonakis, E., Tampakakis, E., Colvin, R.A., Seung, E., Puckett, L., Tai, M.F., Stewart, C.R., Pukkila-Worley, R., Hickman, S.E. et al. (2009) Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J. Exp. Med., 206, 637-53.
43. Andreassi, C., Angelozzi, C., Tiziano, F.D., Vitali, T., De Vincenzi, E., Boninsegna, A., Villanova, M., Bertini, E., Pini, A., Neri, G. et al. (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet., 12, 59-65.
44. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-72.
45. Placantonakis, D.G., Tomishima, M.J., Lafaille, F., Desbordes, S.C., Jia, F., Socci, N.D., Viale, A., Lee, H., Harrison, N., Tabar, V. et al. (2009) BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. Stem Cells, 27, 521-32.
46. Kernochan, L.E., Russo, M.L., Woodling, N.S., Huynh, T.N., Avila, A.M., Fischbeck, K.H. and Sumner, C.J. (2005) The role of histone acetylation in SMN gene expression. Hum. Mol. Genet., 14, 1171-82.
47. Chang, J.G., Hsieh-Li, H.M., Jong, Y.J., Wang, N.M., Tsai, C.H. and Li, H. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA, 98, 9808-13.
48. Febbraio, M., Hajjar, D.P. and Silverstein, R.L. (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest., 108, 785-91.
49. Ren, Y., Silverstein, R.L., Allen, J. and Savill, J. (1995) CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J. Exp. Med., 181, 1857-62.
50. Kunjathoor, V.V., Febbraio, M., Podrez, E.A., Moore, K.J., Andersson, L., Koehn, S., Rhee, J.S., Silverstein, R., Hoff, H.F. and Freeman, M.W. (2002) Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem., 277, 49982-8.